XAGE-1b cancer/testis antigen is a potential target for immunotherapy in prostate cancer.

Abstract

INTRODUCTION Gene-modified cell vaccines are now considered to be the best way to achieve immunotherapy for a variety of cancers including prostate cancer (PCa). XAGE-1b is a member of the cancer/testis antigen family which has demonstrated strong immunogenicity. We investigated whether XAGE-1b is an ideal target for PCa immunotherapy. MATERIALS AND… (More)
DOI: 10.1159/000363333

Topics

Cite this paper

@article{Xie2015XAGE1bCA, title={XAGE-1b cancer/testis antigen is a potential target for immunotherapy in prostate cancer.}, author={Chong Xie and Guomin Wang}, journal={Urologia internationalis}, year={2015}, volume={94 3}, pages={354-62} }